| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.
|
Nat Genet
|
2013
|
5.58
|
|
2
|
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci.
|
Nat Genet
|
2010
|
3.93
|
|
3
|
A common 8q24 variant in prostate and breast cancer from a large nested case-control study.
|
Cancer Res
|
2007
|
3.08
|
|
4
|
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.
|
Nat Genet
|
2011
|
3.07
|
|
5
|
Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.
|
Urology
|
2002
|
2.94
|
|
6
|
Office-based transurethral microwave thermotherapy using the TherMatrx TMx-2000.
|
J Endourol
|
2002
|
2.01
|
|
7
|
Surgeon variation in patient quality of life after radical prostatectomy.
|
J Urol
|
2012
|
2.00
|
|
8
|
Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer.
|
Cancer Res
|
2013
|
1.99
|
|
9
|
Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
|
Eur Urol
|
2012
|
1.81
|
|
10
|
Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression.
|
Hum Mol Genet
|
2013
|
1.78
|
|
11
|
Genetic variation in the HSD17B1 gene and risk of prostate cancer.
|
PLoS Genet
|
2005
|
1.67
|
|
12
|
Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial.
|
Cancer
|
2013
|
1.52
|
|
13
|
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.
|
Hum Mol Genet
|
2012
|
1.47
|
|
14
|
Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers--results from BPC3.
|
PLoS One
|
2011
|
1.41
|
|
15
|
A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3.
|
Hum Mol Genet
|
2011
|
1.36
|
|
16
|
Genome-wide association study identifies multiple loci associated with bladder cancer risk.
|
Hum Mol Genet
|
2013
|
1.34
|
|
17
|
Common genetic variants in prostate cancer risk prediction--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3).
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
1.29
|
|
18
|
A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians.
|
Hum Mol Genet
|
2010
|
1.18
|
|
19
|
Surgical treatment of renal neoplasia: evolving toward a laparoscopic standard of care.
|
Urology
|
2003
|
1.17
|
|
20
|
Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
|
Cancer
|
2007
|
1.09
|
|
21
|
Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride.
|
Eur Urol
|
2013
|
1.02
|
|
22
|
Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
|
J Urol
|
2006
|
1.01
|
|
23
|
Large-scale pathway-based analysis of bladder cancer genome-wide association data from five studies of European background.
|
PLoS One
|
2012
|
1.00
|
|
24
|
Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia.
|
Clin Trials
|
2009
|
0.99
|
|
25
|
Prostate Cancer Early Detection, Version 2.2015.
|
J Natl Compr Canc Netw
|
2015
|
0.98
|
|
26
|
A prospective study of dietary alpha-linolenic acid and the risk of prostate cancer (United States).
|
Cancer Causes Control
|
2006
|
0.97
|
|
27
|
Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
|
Carcinogenesis
|
2013
|
0.96
|
|
28
|
Replication of five prostate cancer loci identified in an Asian population--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3).
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
0.95
|
|
29
|
Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
0.92
|
|
30
|
Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials.
|
Cancer
|
2012
|
0.92
|
|
31
|
Radiation therapy for increasing prostate-specific antigen levels after radical prostatectomy.
|
Clin Prostate Cancer
|
2003
|
0.85
|
|
32
|
Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial.
|
BJU Int
|
2013
|
0.82
|
|
33
|
Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
|
Cancer Epidemiol
|
2012
|
0.81
|
|
34
|
Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.
|
World J Urol
|
2015
|
0.77
|